Viking Therapeutics is gearing up to advance its oral VK2735 weight-loss candidate into Phase 3 trials in the third quarter of 2026, a pivotal step in the competitive obesity treatment market. Despite a recent wider-than-expected loss of $1.38 per share, the company has seen a 16.5% stock increase earlier this year, driven by positive pipeline developments. Analysts remain optimistic about VKTX's potential, yet strong Phase 3 results will be essential in instilling confidence among investors amid ongoing financial scrutiny.
“@CloisterRes You just made a stronger argument for $VKTX in a single X post than its CEO has ever done in all his conference calls and investor presentations.”
“@bioinvestor24 This is a huge $VKTX advantage over tirzepatide.”
“I still think the current best ones (dual GLP-1/GIP drugs like $VKTX's) will stay #1. They drop the same % of weight with similar side effects, plus GLP-1 adds real longevity benefits that amylin probably won't.”
“🚨 Biotech Innovator Alert: $VKTX Viking Therapeutics advancing its oral VK2735 weight-loss candidate toward Phase 3 trials in 2026 while presenting at key investor conferences this week!”
“Clinical biopharma focused on obesity & metabolic disorders (VK2735 Phase 3).”
“$VKTX Insider buy New CCO Ex $LLY guy on board 2026 & 2027 going to be a monumental year for shareholders Stay invested”
“…and VKTX has been for-sale since the start. Any buyer would be a wildly expensive long-shot at viability.”
“Cannot go the path alone for a VKTX.”
“$VKTX consistent positive stock price action lately despite heightened market volatility. Good signs.”
“Like I said earlier, top notch execution by the management team and on the cusp of getting closer to the finish line while major competitors struggling with non-differential data for the Obesity.”
“Viking reported a fourth-quarter 2025 loss of $1.38 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents.”